Richardson Labs' Arthred-G osteoarthritis claims subject of FDA "courtesy letter".
This article was originally published in The Tan Sheet
Executive Summary
RICHARDSON LABS ARTHRED-G CARTILAGE CLAIM DRAWS "COURTESY LETTER" from FDA's Center for Food Safety & Applied Nutrition Office of Special Nutritionals. In the Aug. 6 advisory letter, FDA cites one of the company's registered "structure/function" claims for Arthred-G -- "provides proactive nutritional support for cartilage degeneration" -- which "suggests that [the product] is intended to treat, mitigate, prevent, or cure a disease, namely osteoarthritis". The claim causes the product to be classified as a drug under the FD&C Act, FDA asserts. Richardson Labs has since changed the claim to "provides nutritional support for cartilage regeneration.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.